Seventure Partners backs Skinjay

Skinjay, a French maker of shower micro-nebulization devices, has raised 3.5 million euros in funding. The investor was Seventure Partners.


Paris, France – 26 January, 2017 – Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that from its Health for Life Capital investment vehicle it has invested €3.5 million in Skinjay.

Skinjay, an independent French company founded by Nicolas Pasquier in 2012, develops and markets easy-to-use in-shower micro-nebulization© devices to deliver essential oils to the skin and into the lungs. The funds raised will be used to accelerate the Company’s international expansion and bolster R&D, particularly within respiratory microbiome research.

Skinjay’s product combines a mixer, which is easily affixed to a flexible shower cord, and essential oil capsules. The essential oils vaporize alongside the warm water, giving the user a relaxing shower experience and complementing skin and respiratory tract microbiomes.

“Skinjay’s disruptive and visionary approach to microbiome and wellbeing was very attractive to us. We have always aimed to support innovative-high growth entrepreneurial companies, with a keen interest in the microbiome,” said Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners. “Skinjay is already commercially successful and Nicolas has far-reaching managerial experience, as well as the passion and experience to drive the Company forward.”

About Seventure Partners
With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the life sciences field across Europe and North America.

In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.

Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more details: